The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2019

Filed:

Jul. 05, 2017
Applicant:

The Trustees of Columbia University IN the City of New York, New York, NY (US);

Inventors:

Jan Kitajewski, Ridgewood, NJ (US);

Carrie Shawber, Township of Washington, NJ (US);

Thaned Kangsamaksin, Lampang, TH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C07K 14/735 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 38/177 (2013.01); C07K 14/705 (2013.01); A61K 38/179 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); C07K 14/71 (2013.01); C07K 14/715 (2013.01); C07K 16/283 (2013.01); C07K 19/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01);
Abstract

Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.


Find Patent Forward Citations

Loading…